| XB state . | pCa . | WT tension (mN mm−2) . | . | RBM20-deficient tension (mN mm−2) . | . | ||
|---|---|---|---|---|---|---|---|
| 1.8 µm SL . | 2.2 µm SL . | na . | 1.8 µm SL . | 2.2 µm SL . | na . | ||
| 5 mM ATP | 9.0 | 2.10 ± 0.00 | 5.50 ± 0.10b | 8 | 1.35 ± 0.35c | 2.10 ± 0.00b,c | 7 |
| 4.3 | 20.65 ± 1.55 | 34.10 ± 0.80b | 17.65 ± 1.65c | 26.55 ± 0.55b,c | |||
| 5 mM ADPd | 9.0 | 12.87 ± 2.70 | 37.30 ± 4.12b | 8 | 8.30 ± 0.90 | 28.03 ± 5.02b,c | 7 |
| 4.3 | 17.85 ± 1.95 | 37.55 ± 0.25b | 12.85 ± 0.35c | 26.45 ± 0.35b,c | |||
| 1 mM Vie | 9.0 | 2.05 ± 1.55 | 8.90 ± 0.30b | 6 | 1.40 ± 1.20 | 5.20 ± 1.30b,c | 6 |
| 4.3 | 2.35 ± 0.15 | 11.90 ± 0.50b | 1.75 ± 0.55 | 7.45 ± 0.85b,c | |||
| XB state . | pCa . | WT tension (mN mm−2) . | . | RBM20-deficient tension (mN mm−2) . | . | ||
|---|---|---|---|---|---|---|---|
| 1.8 µm SL . | 2.2 µm SL . | na . | 1.8 µm SL . | 2.2 µm SL . | na . | ||
| 5 mM ATP | 9.0 | 2.10 ± 0.00 | 5.50 ± 0.10b | 8 | 1.35 ± 0.35c | 2.10 ± 0.00b,c | 7 |
| 4.3 | 20.65 ± 1.55 | 34.10 ± 0.80b | 17.65 ± 1.65c | 26.55 ± 0.55b,c | |||
| 5 mM ADPd | 9.0 | 12.87 ± 2.70 | 37.30 ± 4.12b | 8 | 8.30 ± 0.90 | 28.03 ± 5.02b,c | 7 |
| 4.3 | 17.85 ± 1.95 | 37.55 ± 0.25b | 12.85 ± 0.35c | 26.45 ± 0.35b,c | |||
| 1 mM Vie | 9.0 | 2.05 ± 1.55 | 8.90 ± 0.30b | 6 | 1.40 ± 1.20 | 5.20 ± 1.30b,c | 6 |
| 4.3 | 2.35 ± 0.15 | 11.90 ± 0.50b | 1.75 ± 0.55 | 7.45 ± 0.85b,c | |||
pCa, −log10 of free Ca2+ concentration; SL, sarcomere length.
Number of fibers used in each set of measurements.
Compared with 1.8 µm sarcomere length at each condition (P < 0.05).
Compared with WT at the same cross-bridge condition, sarcomere length, and Ca2+ activation state (P < 0.05).
ATP was absent in ADP solutions.
Vi solutions also contained 5 mM ATP.